Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831Phase 2Recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in Crohn's disease, sponsored by Boston Children's Hospital. Primary endpoints: Number of subjects with serious and non-serious adverse events at 8 weeks and Maximum effective dose at 8 weeks. Started Mar 2021; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04263831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263831.